

# General Index

---

<b>Chapter I: General Introduction</b> .....	<b>31</b>
<b>I.1 Immune System</b> .....	<b>33</b>
<b>I.2 Inflammatory Response</b> .....	<b>36</b>
I.2.1 Inflammation-inducing Agents (Inducers).....	39
I.2.2 Pattern Recognition Receptors (PRRs) (sensors) .....	40
I.2.3 Mediators of Inflammation .....	43
I.2.4 Effectors of Inflammation .....	43
<b>I.3 Inflammasomes</b> .....	<b>44</b>
1.3.1 Inflammasomes as therapeutic targets.....	47
<b>I.4 ASC adapter protein</b> .....	<b>49</b>
I.4.1 ASC-dependent inflammasomes.....	51
I.4.2. ASC-dependent Inflammasomes in disease.....	55
I.4.3 Current therapeutics approaches for inflammasome inhibition .....	61
<b>I.5 Breast Cancer at a Glance</b> .....	<b>65</b>
I.5.1 Current Therapeutic Approaches for Breast Cancer .....	68
<b>I.6 Nanomedicine for Breast Cancer Treatment: Classification and Key Design Features.</b> .....	<b>70</b>
I.6.1 Understanding the biological Barriers .....	72
I.6.2 The Enhanced Permeability and Retention (EPR) Effect .....	75
I.6.3 Currently used Nanomedicines in Breast Cancer Treatment.....	76
<b>I.7 Polymer Therapeutics</b> .....	<b>79</b>
I.7.1 Definition and Classification of Polymer Therapeutics .....	79
<b>I.8 Polymer Conjugates as Therapeutics</b> .....	<b>81</b>
I.8.1 Polymer-drug Conjugates as Therapeutics .....	84

I.8.2 Rational Design of Polymer-Drug Conjugates .....	88
<b>I.9 Polypeptide-Based drug Conjugates as therapeutics.....</b>	<b>92</b>
<b>I.10 References .....</b>	<b>93</b>
<b>Chapter II: Objectives .....</b>	<b>103</b>
<b>Chapter III: Materials and Methods.....</b>	<b>107</b>
<b>III.1. Materials .....</b>	<b>109</b>
III.1.1 Chemical and biological agents.....	109
III.1.2 Cell lines and culture conditions .....	110
III.1.3 Antibodies .....	111
III.1.4 Animals .....	112
<b>III.2. Methods.....</b>	<b>112</b>
III.2.1 <i>In vitro</i> assays.....	112
III.2.2 Cellular assays.....	114
III.2.3 <i>In vivo</i> assays.....	122
III.2.4 Proteomic studies .....	125
III.2.5 PGA-MM01 synthesis.....	127
III.2.6 Statistical analysis .....	132
<b>Chapter IV: Molecular mechanism of action and pharmacological activity of the novel inflammasome inhibitor MM01.....</b>	<b>133</b>
<b>Graphical Abstract .....</b>	<b>135</b>
<b>Antecedents and Background.....</b>	<b>136</b>
<b>Abstract .....</b>	<b>137</b>
<b>Results and Discussion .....</b>	<b>138</b>
<b>IV.1 Identification of a Novel ASC Oligomerization Inhibitor .....</b>	<b>138</b>
IV.1.1 MM01 Prevents ASC Oligomerization <i>in vitro</i> .....	139
IV.1.2 MM01 Inhibits ASC Oligomerization in a Cellular Context.....	140

IV.1.3 MM01 inhibits ASC Speck Formation in Macrophages Expressing ASC-GFP.....	145
<b>IV.2 Identification of MM01 Binding Sites in ASC .....</b>	<b>151</b>
IV.2.1 Study of the MM01 ASC Binding site.....	153
<b>IV.3. MM01 Inhibits ASC-mediated Inflammatory Signaling <i>in vitro</i> .....</b>	<b>158</b>
IV.3.1 MM01 Prevents NLRP3 Activation in THP-1 -derived Monocytes and Macrophages .....	158
IV.3.2 MM01 Prevents AIM2 Inflammasome Activation in THP-1-ASC-GFP-derived Macrophages .....	161
IV.3.3 MM01 Inhibits Pyrin Inflammasome Activation in THP-1-ASC-GFP-derived Macrophages .....	163
IV.3.4 MM01 Fails to Inhibit Non-canonical Inflammasome Activation in THP-1-ASC-GFP-derived Macrophages .....	165
<b>IV.4 MM01 Inhibits ASC-mediated Inflammatory Signaling <i>in vivo</i> .....</b>	<b>167</b>
IV.4.1 MM01 Inhibits NLRP3 Activation in a Mouse Model of MSU-induced Peritonitis .....	168
IV.4.2 MM01 Inhibits NLRP3 Inflammasome Activation in a Mouse Model of MSU-induced Peritonitis .....	169
<b>Conclusions.....</b>	<b>171</b>
<b>Chapter V: The role of the inflammasome in Breast Cancer .....</b>	<b>175</b>
<b>Graphical Abstract .....</b>	<b>177</b>
<b>Antecedents and Background.....</b>	<b>177</b>
<b>Abstract .....</b>	<b>181</b>
<b>Results and Discussion .....</b>	<b>181</b>
<b>V.1 Characterization of Inflammasome Inhibition in Breast Cancer Models .....</b>	<b>181</b>
V.1.1 Characterization of Human and Murine Macrophage-based Models.....	182

V.1.2 MM01 Prevents Inflammasome Activation in Pro-inflammatory Macrophages .....	185
V.1.3 Pro-inflammatory M1 Macrophages Influence Breast Cancer Cell Migration in a Subtype-dependent Manner.....	189
<b>V.2. <i>In vivo</i> Validation of Inflammasome Inhibition in Breast Cancer .....</b>	<b>195</b>
V.2.1 Development of Stable Luciferase-expressing EO771 Cells .....	195
V.2.2 Optimization of the Orthotopic Luciferase-expressing EO771 Mouse Model .....	197
V.2.3 Study of MM01 Antitumor ActVity and Safety in the EO771 Murine Model .....	200
V.2.4 Study of MM01 Antitumor ActVity and Safety in the.....	203
<b>V.3 Identification of Biomarkers of Response to MM01 Treatment .....</b>	<b>207</b>
V.3.1 Inflammasome-related Proteins Fail to Impact EO771 and 4T1 Migration .....	207
V.3.2 Proteomic Analysis of Responder and Non-responder Breast Cancer Cells .....	210
<b>Conclusions.....</b>	<b>218</b>
<b>Chapter VI: A Rationally Designed Polypeptide-based MM01 Nanomedicine Improves Antitumor Efficacy in Breast Cancer Models.....</b>	<b>223</b>
<b>Graphical Abstract.....</b>	<b>225</b>
<b>Antecedents and Background.....</b>	<b>225</b>
<b>Abstract .....</b>	<b>227</b>
<b>Results and Discussion .....</b>	<b>227</b>
<b>VI.1 Synthesis of an MM01 Nanomedicine .....</b>	<b>227</b>
VI.1.1 Development of the L-PGA- $\beta$ CD: Synthesis and Physico-Chemical Characterization .....	227

VI.1.2 Development of L-PGA- $\beta$ CD Encapsulated MM01: Synthesis and Physico-Chemical Characterization .....	232
<b>VI.2 The <i>in vitro</i> Evaluation and Selection of an Optimal Nanomedicine Candidate .....</b>	<b>237</b>
VI.2.1 Selection of L-PGA- $\beta$ CD-MM01-3 as the Optimal Candidate .....	238
VI.2.2 Candidate validation: L-PGA- $\beta$ CD-MM01-3 .....	239
VI.2.3 L-PGA- $\beta$ CD-MM01-3 and L-PGA- $\beta$ CD-MM01-8 Prevent NLRP3 Activation in THP-1 derived Macrophages .....	242
<b>VI.3 Therapeutic Efficacy of L-PGA-<math>\beta</math>CD-MM01-3 in Breast Cancer Models .....</b>	<b>245</b>
VI.3.1 L-PGA- $\beta$ CD-MM01-3 treatment affect migration dependent upon breast cancer subtype .....	245
<b>VI.4 <i>In vivo</i> Validation of L-PGA-<math>\beta</math>CD-MM01-3 in a Breast Cancer Model</b>	<b>248</b>
V.4.1 L-PGA- $\beta$ CD-MM01-3 Antitumor Activity and Safety in the EO771 TNBC Murine Model.....	248
<b>Conclusions.....</b>	<b>252</b>
<b>General Discussion.....</b>	<b>255</b>

